Vimta Labs Ltd
Vimta Labs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Vimta Labs aims to maintain a strong CAGR similar to the last 5-7 years, targeting INR 500 crores in annualized revenue by FY27. Vimta Labs targets maintaining a strong CAGR seen over the last 5-7 years, aiming for INR 500 crores annual revenue run rate by FY27 despite some recent headwinds.
From Vimta Labs Ltd's Q4 FY26 earnings-call transcript · updated 24 Aug 2026.
Revenue & Sales Performance
- Vimta Labs aims to maintain a strong CAGR similar to the last 5-7 years, targeting INR 500 crores in annualized revenue by FY27.
- Growth drivers include pharmaceuticals, food testing, and electronics, with good visibility and expanding markets.
- The company anticipates continued robust demand, especially in pharma analytical and biologics contract research.
- Electronics and electrical testing are expected to gain momentum post fixing leadership challenges.
- Biologics contract research is set to commence in FY27, with efforts underway to onboard clients.
- Expansion facilities are planned to support growth for the next 4-5 years.
- Despite geopolitical and economic uncertainties, Vimta remains hopeful to sustain and grow revenue momentum.
2 more points from Vimta Labs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Currently, there is no firm or concrete plan for raising funds through methods like rights issues for ramping up the capex, as per Harita Vasireddi (Page 13).
- The company has recently moved into new facilities that are designed to support growth for the next 4-5 years (Page 11).
- Utilization of the new facility is expected to pick up gradually over this year and the next (Page 11).
- There are no specific plans mentioned for acquisitions or capacity expansions at present, but management will announce if something materializes (Page 12).
2 more points from Vimta Labs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Vimta Labs has reported good inquiries and traction for new projects.
- They have promising prospects from Europe, India, and some from the US.
- Finalizations for product and modality of these projects are underway.
- Some biologics contract research projects are under discussion, with hopes of materializing soon.
- While no concrete plans for acquisitions or major expansions are firmed up, the company is exploring potential opportunities.
- Management is confident about maintaining revenue momentum with an aim to keep quarterly revenues around INR120-130 crores.
2 more points from Vimta Labs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Vimta Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹109 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnos. (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnos.'s Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Arthneeti Pro · Annual
Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vimta Labs Ltd Q4 FY26 results?
Vimta Labs aims to maintain a strong CAGR similar to the last 5-7 years, targeting INR 500 crores in annualized revenue by FY27. Vimta Labs targets maintaining a strong CAGR seen over the last 5-7 years, aiming for INR 500 crores annual revenue run rate by FY27 despite some recent headwinds.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.8 with a market cap of ₹2,814 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Currently, there is no firm or concrete plan for raising funds through methods like rights issues for ramping up the capex, as per Harita Vasireddi (Page 13).
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.